Taejoon Pharmaceutical Co., Ltd.
Quick facts
Marketed products
- Taflotan-S
- TJO-018 (HA 0.15%) · Ophthalmology
TJO-018 is a hyaluronic acid-based topical formulation that provides lubrication and moisture retention to the ocular surface. - Xalost S
Phase 3 pipeline
- Conventional OST · Orthopedics / Regenerative Medicine
Conventional OST (Osteogenic Stem Cell Therapy) promotes bone formation and regeneration by utilizing osteogenic stem cells to stimulate new bone growth. - Cool prep · Gastroenterology
Cool prep is a bowel preparation agent designed to cleanse the colon prior to colonoscopy procedures. - Coolprep powder · Cardiovascular
Coolprep powder is a medication used to treat hypercholesterolemia by inhibiting the absorption of dietary cholesterol. - CTP0301-A · Diabetes
CTP0301-A is a small molecule that targets the SGLT2 receptor. - CTP0301-B · Diabetes
CTP0301-B is a small molecule that targets the SGLT2 receptor. - CTP0302-A · Diabetes
CTP0302-A is a small molecule that targets the SGLT2 receptor. - CTP0302-B · Diabetes
CTP0302-B is a small molecule that targets the SGLT2 receptor. - CTP0303
CTP0303 is an investigational therapeutic in phase 3 development by Taejoon Pharmaceutical, but its specific mechanism of action is not publicly disclosed. - Cyclosporine ophthalmic solution 0.05% · Ophthalmology
Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation and reduces inflammatory cytokine production in the eye. - Diquafosol ophthalmic sodium solution 3% · Ophthalmology
Diquafosol is a P2Y2 purinergic receptor agonist that stimulates secretion of mucin and aqueous fluid from conjunctival and lacrimal glands to increase tear production. - Orafang Tab · Cardiovascular
Orafang is an oral anticoagulant that inhibits Factor Xa in the coagulation cascade to prevent thrombus formation. - TJO-002 · Diabetes
TJO-002 is a small molecule that targets the SGLT2 receptor. - TJO-083 · Diabetes
TJO-083 is a small molecule that targets the SGLT2 receptor. - TJO-087 · Diabetes
TJO-087 is a small molecule that targets the SGLT2 receptor. - TJP-008-1 · Diabetes
TJP-008-1 is a small molecule that targets the SGLT2 receptor. - TJP-008-2 · Diabetes
TJP-008-2 is a small molecule that targets the SGLT2 receptor.
Phase 2 pipeline
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: